Since we identified Bmal1 as a pivotal mediator in cisplatin-induced renal injury, and the therapeutic intervention targeting Bmal1 in the kidney may be a promising strategy to minimize the toxic side-effects of cisplatin in its clinical applications, this would raise a serious concern that the anti-tumor effect of cisplatin may be reduced while decreasing the toxic side-effect of cisplatin with Bmal1 manipulation. This evidence concerns the gene BMAL1 and neoplasm.